Navigation Links
MacroGenics to Receive $10 Million Milestone Payment from Servier for Dosing the First Patient in a Phase 1 Dose Expansion Trial of MGA271
Date:8/20/2013

ROCKVILLE, Md., Aug. 20, 2013 /PRNewswire/ -- MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, announced that the first patient has been dosed in a Phase 1 dose expansion cohort trial of MGA271.  MGA271 is an Fc-optimized monoclonal antibody that targets B7-H3, which is over-expressed on a wide variety of solid tumor types and is a member of the B7 family of molecules that are involved in immune regulation.  This milestone triggers a $10 million payment to MacroGenics from its partner, Les Laboratoires Servier, or Servier.

The dose expansion portion of this Phase 1 clinical trial of MGA271 is designed to further evaluate safety and pharmacokinetics at a weekly dose of 15 mg/kg.  The dose expansion portion of the trial also includes an early evaluation of the potential anti-tumor activity of MGA271.  MacroGenics plans to enroll 45 patients within three cohort groups: two with specific tumor types of 15 patients each, and a third cohort composed of other B7-H3-expressing tumor types.  MacroGenics is enrolling patients in the United States and expects to complete the Phase 1 trial in 2014.  Servier has indicated that it intends to evaluate MGA271 in 45 additional cancer patients representing additional tumor types beginning in the fourth quarter of 2013.

"MGA271 has significant potential to treat a variety of solid tumors and we are very pleased to reach this milestone in the product candidate's ongoing development," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics.  "We intend to assess and prioritize future indications for MGA271 clinical trials based on data from these dose expansion cohorts and determine the best pat
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer
2. MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
3. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
4. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
5. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
6. Retired Pro Hockey Player 1st to Receive Total Artificial Heart in Upstate New York
7. Sensitech Inc. Products Receive Regulatory Compliance Approval from IATA
8. Nephros Receives 510(k) Clearance for Hemodiafiltration System
9. ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System
10. BONESUPPORT Receives Red Herring 2012 Top 100 Europe Award
11. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... VIEJO, Calif. , Nov. 26, 2014 /PRNewswire/ ... announced that the U.S. Food and Drug Administration ... its New Drug Application (NDA) for AVP-825. AVP-825 ... low-dose sumatriptan powder delivered intranasally utilizing a novel ... the Complete Response letter, and consistent with the ...
(Date:11/26/2014)...  BioScrip ® , Inc. (NASDAQ: BIOS ) announced ... Officer, will present at the Bank of America Merrill Lynch 2014 ... Date: , , , Wednesday, December 3, 2014 , , ... , , , Location: , , , Boca Raton Resort and ... BioScrip, Inc. is a leading national provider ...
(Date:11/26/2014)... , Nov. 26, 2014  Aridis Pharmaceuticals, Inc., ... novel therapies for infectious diseases, announced today the ... internationally recognized key opinion leader in the areas ... advisory board. Founder and Chief Executive ... believe Dr. Opal,s extensive experience investigating bacterial toxins ...
Breaking Medicine Technology:Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... According to the American,Academy of Dermatology (AAD), ... an inflamed skin condition characterized by red, scaly,and ... which tend to,flare up in the winter months, ... Eczema Care Moisturizing Cream and Body Wash, formulated,with ...
... Infection Control, WASHINGTON, Jan. 10 To ... minimize risks during times,of health crisis, DuPont (NYSE: ... its,healthcare products, DuPont(TM) Corian(R) solid surface, has been ... department. The product,recently was incorporated into a children,s ...
Cached Medicine Technology:New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema 2DuPont Provides Technology for Washington Hospital Center's Emergency Department 2DuPont Provides Technology for Washington Hospital Center's Emergency Department 3DuPont Provides Technology for Washington Hospital Center's Emergency Department 4
(Date:11/27/2014)... HealthDay Reporter WEDNESDAY, Nov. 26, 2014 ... safe and produces an immune system response that could protect ... results reported by the U.S. National Institutes of Health. ... vaccine paves the way for field-testing it in the Ebola-stricken ... as January, said Dr. Anthony Fauci, director of the NIH,s ...
(Date:11/27/2014)... NY (PRWEB) November 27, 2014 The founders ... offering stylish, comfortable and high functioning compression socks, are proud ... newly-released socks use an innovative Gradient Pressure (TM) knitting technology ... blood. , VIM & VIGR’s commitment to adding flair and ... as just functional recently caught the eye of a writer ...
(Date:11/27/2014)... November 27, 2014 Tylenol lawsuits ( ... allegedly injured by the medication are continuing to move ... is looking ahead to a status conference in December, ... Scheduling Order issued earlier this year, a conference in ... at 10:00 a.m. Items likely to be discussed at ...
(Date:11/27/2014)... 2014 “Wekho” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers ... , An interesting new way to travel and experience the ... It’s called Wekho and it’s a free geolocation app ...
(Date:11/27/2014)... 2014 Dr. Ronald Receveur, who has a ... few oral health tips before patients dig into the annual ... New Albany affordable cosmetic dentistry, and his staff ... and sugar. While the staff wishes everyone a happy and ... how patients can enjoy a feast that is also healthy ...
Breaking Medicine News(10 mins):Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 3Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 4
... The acquisition of Baptist Memorial Hospital in Forrest City, ... Systems. The acute health care centre which is 118-bedded ... Ark.). // ,In addition, some other assets would ... care center (Memphis-based Baptist Memorial Health Care Corp.) The ...
... new online application system for junior doctor posts is not ... the job prospects of many top students. This was the ... system being followed is the “Modernising Medical Careers system” which ... answers. ,The reason for this attack as claimed ...
... Scientists at the U.S. Department of Energy’s Brookhaven ... identifying the many species of microorganisms. They have ... of Applied Environmental Microbiology. Microbiology has many applications ... species useful for cleaning up contamination, to identify ...
... and weight loss failure turned to an online competition to ... a 4 month period.//, ,The competition hosted on WeightLossWars.com ... 25 miles, with the winner of the competition losing 9% ... Jen sending out invitations through WeightLossWars.com to her family and ...
... in matters of sleep till late the reason being ... ray of new light comes the IST project 'Sensation' ... different // countries, addressing sensing of physiological parameters, core ... a multipurpose sensing platform consisting of 17 micro sensors ...
... the protective clothing to astronauts going to space and ... the basis to design// protective clothing for fire fighters ... heat and dangerous circumstances. ,This project nicknamed ... that encompasses an inbuilt cooling system, with a technology ...
Cached Medicine News:Health News:Online recruitment criticised by doctors 2Health News:The Novel Cut and Splice Method Is Used To Recognize Different Microbes 2Health News:Sleep Science awakens from deep slumber! 2
Batch Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 40 tests....
For use with catalog #0540....
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Detection of Lupus Anticoagulants. Freeze-dried hexagonal phase phos-phatidylethanolamine; normal plasma with heparin inhibitor; PTT-LS reagent of cephalin and particulate siliceous activator;all fre...
Medicine Products: